The use of antiangiogenic and antiresorptive medications, particularly in patients with cancer or osteoporosis, can lead to osteonecrosis of the jaw following tooth extraction, trauma or arising spontaneously- A condition known as medication-related osteonecrosis of the jaw (MRONJ). In this article, we present a unique case of MRONJ in a patient with no history of antiresorptive or antiangiogenic drug use, who was instead taking the anti-interleukin 17-A (Secukinumab) medication for severe psoriasis. This association has not been previously reported in the literature.

Department of Anatomy Faculty of Medicine in Pilsen Charles University Pilsen 32300 Czech Republic

Department of Stomatology University Hospital Pilsen Faculty of Medicine in Pilsen Charles University Pilsen 32300 Czech Republic

Zobrazit více v PubMed

Kim BS, Shin BS. Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea. Therap Adv Chronic Dis. 2024;26(15):20406223241230180. PubMed PMC

Li L, Liu K, Duan X, Xu L, Yang Q, Liu F. A Comparison of Clinical Characteristics in Overweight/Obese and Normal Weight Patients with Psoriasis Vulgaris: a Bicentric Retrospective Observational Study. Clin Cosmet Invest Dermatol. 2023;30(16):1377–1385. PubMed PMC

Sbidian E, Chaimani A, Guelimi R, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2023;7(7):CD011535. doi:10.1002/14651858.CD011535.pub6 PubMed DOI PMC

Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clinical Med. 2021;21(3):170–173. PubMed PMC

Novianti Y, Hidayat W, Rosa DE. Severe Xerostomia Induced by Multiple Systemic Diseases in a Patient with Psoriasis Vulgaris: a Case Report and Literature Review. Int Medi Case Reports J. 2024;31(17):77–88. PubMed PMC

Bucur S, Serban ED, Ileanu BV, et al. Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis: real-World Data from Bucharest, Romania. Psoriasis: Targets and Ther. 2024;25(14):79–86. PubMed PMC

Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the jaws—2022 update. J Oral Maxillofacial Surg. 2022;80(5):920–943. PubMed

Wang F, Wei S, Zhang Z, Sun B. Osimertinib: another medication related to osteonecrosis of the jaws? A case report and literature review. Front Pharmacol. 2022;10(13):947947. PubMed PMC

Samieirad S, Labafchi A, Famili K, Hashemzadeh H. Medication-Related Osteonecrosis of the Jaw (MRONJ) due to simvastatin: an unusual case report. World J Plastic Sur. 2021;10(1):132–135. PubMed PMC

Hauer L, Jambura J, Hrusak D, et al. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020;164(1):100–107. PubMed

Suryani IR, Ahmadzai I, Shujaat S, Ma H, Jacobs R. Non-antiresorptive drugs associated with the development of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. Clin Oral Investig. 2022;26(3):2269–2279. PubMed

Liu C, Xiong YT, Zhu T, Liu W, Tang W, Zeng W. Management of Tooth Extraction in Patients Taking Antiresorptive Drugs: an Evidence Mapping Review and Meta-Analysis. J Clin Med. 12(1):239. PubMed PMC

Roh T, Jo H, Kim JY. Maxillary Bone Necrosis in Post-COVID-19 Patients: possibility of Medication-Related Osteonecrosis of Jaws (MRONJ) Induced by Tocilizumab. J Craniofacial Surgery. 2024;35(5):e454–e457. PubMed

Sakkas A, Heil S, Kargus S, Rebel M, Mischkowski RA, Thiele OC. Tocilizumab: another medication related to osteonecrosis of the jaws? A case report and literature review. GMS Interdiscipl Plastic Reconstruc Surg DGPW. PubMed PMC

Marotta M, Boffano P, Prota E, et al. Guselkumab: a new etiological factor of medication- related osteonecrosis of the jaw (MRONJ)? A case report. J Stomatol Oral Maxillofac Surg. 2024;101985. PubMed

Sacco R, Shah S, Leeson R, et al. Osteonecrosis and osteomyelitis of the jaw associated with tumour necrosis factor-alpha (TNF-α) inhibitors: a systematic review. Br J Oral Maxillofac Surg. 2020;58(1):25–33. PubMed

Aghaloo TL, Tetradis S. Osteonecrosis of the jaw in the absence of antiresorptive or antiangiogenic exposure: a series of 6 cases. J Oral Maxillofacial Surg. 2017;75(1):129–142. PubMed PMC

Brijs K, Miclotte I, Vermeire S, Darche V, Politis C. Osteonecrosis of the jaw in patients with inflammatory bowel disease treated with tumour necrosis factor alpha inhibitors. Int J Oral Maxillofacial Surg. 2020;49(3):317–324. PubMed

Milosavljević M, Jovanović M, Folić M, et al. Possible association of methotrexate use with osteonecrosis of the jaw: systematic review. J Stomat Oral Maxillofacial Su. 2022;123(5):e458–e463. PubMed

Jiang A, Zhang Z, Qiu X, Guo Q. Medication-related osteonecrosis of the jaw (MRONJ): a review of pathogenesis hypothesis and therapy strategies. Arch Toxicol. 2024;98(3):689–708. PubMed

Zhang W, Gao L, Ren W, et al. The Role of the Immune Response in the Development of Medication-Related Osteonecrosis of the Jaw. Front Immunol. 2021;12:606043. PubMed PMC